HRP20220720T1 - Analozi egf(a) s masnim kiselinama kao supstituentima - Google Patents
Analozi egf(a) s masnim kiselinama kao supstituentima Download PDFInfo
- Publication number
- HRP20220720T1 HRP20220720T1 HRP20220720TT HRP20220720T HRP20220720T1 HR P20220720 T1 HRP20220720 T1 HR P20220720T1 HR P20220720T T HRP20220720T T HR P20220720TT HR P20220720 T HRP20220720 T HR P20220720T HR P20220720 T1 HRP20220720 T1 HR P20220720T1
- Authority
- HR
- Croatia
- Prior art keywords
- egf
- gglu
- hooc
- 301leu
- 2xado
- Prior art date
Links
- 125000005313 fatty acid group Chemical group 0.000 title claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 238000006467 substitution reaction Methods 0.000 claims 16
- 239000000126 substance Substances 0.000 claims 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 238000002965 ELISA Methods 0.000 claims 3
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 claims 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- -1 methylsulfonylcarbamoylamino residue Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical group OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 claims 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 claims 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 229940125877 compound 31 Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016070791 | 2016-01-13 | ||
| CN2016076580 | 2016-03-17 | ||
| EP16195965 | 2016-10-27 | ||
| PCT/EP2017/050668 WO2017121850A1 (en) | 2016-01-13 | 2017-01-13 | Egf(a) analogues with fatty acid substituents |
| EP17701078.2A EP3402811B1 (en) | 2016-01-13 | 2017-01-13 | Egf(a) analogues with fatty acid substituents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220720T1 true HRP20220720T1 (hr) | 2022-09-30 |
Family
ID=57868232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220720TT HRP20220720T1 (hr) | 2016-01-13 | 2017-01-13 | Analozi egf(a) s masnim kiselinama kao supstituentima |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10822385B2 (enExample) |
| EP (1) | EP3402811B1 (enExample) |
| JP (2) | JP6797926B2 (enExample) |
| KR (1) | KR102417487B1 (enExample) |
| CN (1) | CN108473550B (enExample) |
| AU (1) | AU2017207862B2 (enExample) |
| BR (1) | BR112018013820A2 (enExample) |
| CA (1) | CA3010756A1 (enExample) |
| CL (1) | CL2018001868A1 (enExample) |
| CO (1) | CO2018007440A2 (enExample) |
| DK (1) | DK3402811T3 (enExample) |
| ES (1) | ES2916998T3 (enExample) |
| HR (1) | HRP20220720T1 (enExample) |
| HU (1) | HUE058647T2 (enExample) |
| IL (1) | IL260043A (enExample) |
| LT (1) | LT3402811T (enExample) |
| MX (1) | MX2018008681A (enExample) |
| MY (1) | MY195199A (enExample) |
| PE (1) | PE20181376A1 (enExample) |
| PH (1) | PH12018501502A1 (enExample) |
| PL (1) | PL3402811T3 (enExample) |
| RS (1) | RS63298B1 (enExample) |
| RU (1) | RU2747877C2 (enExample) |
| SA (1) | SA518391996B1 (enExample) |
| SI (1) | SI3402811T1 (enExample) |
| WO (1) | WO2017121850A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60224B1 (sr) | 2016-01-13 | 2020-06-30 | Gruenenthal Gmbh | Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
| HRP20250176T1 (hr) | 2016-01-13 | 2025-04-11 | Grünenthal GmbH | Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
| AU2017207862B2 (en) | 2016-01-13 | 2020-12-17 | Novo Nordisk A/S | EGF(A) analogues with fatty acid substituents |
| JP6917379B2 (ja) | 2016-01-13 | 2021-08-11 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体 |
| AR107360A1 (es) | 2016-01-13 | 2018-04-25 | Gruenenthal Gmbh | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
| WO2019016306A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | BIFUNCTIONAL COMPOUNDS |
| CN111164098A (zh) * | 2017-07-19 | 2020-05-15 | 诺沃挪第克公司 | Egf(a)类似物、其制品、制剂和用途 |
| WO2019023295A1 (en) * | 2017-07-27 | 2019-01-31 | Saint Louis University | Fatty acid modified human epidermal growth factor |
| JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| MA53809A (fr) * | 2018-10-05 | 2022-01-12 | Novo Nordisk As | Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a) |
| US11633632B2 (en) | 2019-03-22 | 2023-04-25 | 3M Innovative Properties Company | Fall-protection system with monitoring system |
| CN110357969B (zh) * | 2019-05-27 | 2022-03-08 | 北京志道生物科技有限公司 | 一种GLP1-EGFa异源二聚体蛋白、功能及方法 |
| CN114222581A (zh) | 2019-08-07 | 2022-03-22 | 诺和诺德股份有限公司 | 包含egf(a)衍生物和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物 |
| AU2020378624A1 (en) | 2019-11-07 | 2022-04-21 | Novo Nordisk A/S | Solid compositions comprising a PCSK9 inhibitor and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| JP2024527488A (ja) | 2021-07-02 | 2024-07-25 | スリーエム イノベイティブ プロパティズ カンパニー | 落下防止安全装置と連動される空中リフト |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909823A2 (en) | 2005-07-29 | 2008-04-16 | Amprotein Corporation | Chimeric therapeutic agents |
| EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| EP2178910B1 (en) | 2007-08-15 | 2014-10-08 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| MX2010011499A (es) * | 2008-04-23 | 2010-11-12 | Amgen Inc | Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos. |
| US8673850B2 (en) | 2008-05-30 | 2014-03-18 | Institut De Recherches Cliniques De Montreal | PCSK9 inhibitors and methods of use thereof |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| CN103052900A (zh) * | 2010-08-02 | 2013-04-17 | 日本电气株式会社 | 偏振器和发光装置 |
| CN102153652A (zh) | 2010-12-10 | 2011-08-17 | 浙江大学 | 一种融合蛋白的表达方法及用途 |
| EP2675470A1 (en) | 2011-02-15 | 2013-12-25 | Novo Nordisk A/S | Long-acting il-1 receptor antagonists |
| MX2013015311A (es) * | 2011-06-20 | 2014-03-31 | Genentech Inc | Polipeptidos de enlace de pcsk9 y metodos de uso. |
| CA2849673A1 (en) * | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| EP2794648A1 (en) * | 2011-12-21 | 2014-10-29 | Novo Nordisk A/S | N-terminally modified insulin derivatives |
| EP2851429B1 (en) | 2012-05-18 | 2019-07-24 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
| AR092076A1 (es) | 2012-08-22 | 2015-03-18 | Lilly Co Eli | Proteinas homodimericas |
| SG11201500682WA (en) | 2012-09-07 | 2015-02-27 | Sanofi Sa | Fusion proteins for treating a metabolic syndrome |
| PL2986313T3 (pl) * | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| BR112016017402A2 (pt) | 2014-02-21 | 2017-10-17 | Medimmune Ltd | fusões anti-pcsk9~glp-1 e métodos para uso |
| JP2017525656A (ja) * | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| CN104558198A (zh) | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 |
| CA2979617C (en) * | 2015-03-19 | 2024-01-02 | Institut De Cardiologie De Montreal | Grp94 derived polypeptides for inhibiting pcsk9 and methods of use |
| CN105367884A (zh) | 2015-11-02 | 2016-03-02 | 陈薇 | 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法 |
| AU2017207862B2 (en) | 2016-01-13 | 2020-12-17 | Novo Nordisk A/S | EGF(A) analogues with fatty acid substituents |
| WO2019016306A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | BIFUNCTIONAL COMPOUNDS |
| CN111164098A (zh) | 2017-07-19 | 2020-05-15 | 诺沃挪第克公司 | Egf(a)类似物、其制品、制剂和用途 |
-
2017
- 2017-01-13 AU AU2017207862A patent/AU2017207862B2/en not_active Ceased
- 2017-01-13 ES ES17701078T patent/ES2916998T3/es active Active
- 2017-01-13 MY MYPI2018702319A patent/MY195199A/en unknown
- 2017-01-13 MX MX2018008681A patent/MX2018008681A/es unknown
- 2017-01-13 HR HRP20220720TT patent/HRP20220720T1/hr unknown
- 2017-01-13 EP EP17701078.2A patent/EP3402811B1/en active Active
- 2017-01-13 US US16/069,932 patent/US10822385B2/en active Active
- 2017-01-13 WO PCT/EP2017/050668 patent/WO2017121850A1/en not_active Ceased
- 2017-01-13 BR BR112018013820-7A patent/BR112018013820A2/pt not_active Application Discontinuation
- 2017-01-13 DK DK17701078.2T patent/DK3402811T3/da active
- 2017-01-13 PE PE2018001257A patent/PE20181376A1/es unknown
- 2017-01-13 RU RU2018127882A patent/RU2747877C2/ru active
- 2017-01-13 PL PL17701078T patent/PL3402811T3/pl unknown
- 2017-01-13 KR KR1020187022105A patent/KR102417487B1/ko active Active
- 2017-01-13 CA CA3010756A patent/CA3010756A1/en not_active Withdrawn
- 2017-01-13 HU HUE17701078A patent/HUE058647T2/hu unknown
- 2017-01-13 JP JP2018536444A patent/JP6797926B2/ja active Active
- 2017-01-13 LT LTEPPCT/EP2017/050668T patent/LT3402811T/lt unknown
- 2017-01-13 SI SI201731149T patent/SI3402811T1/sl unknown
- 2017-01-13 CN CN201780006783.6A patent/CN108473550B/zh active Active
- 2017-01-13 RS RS20220538A patent/RS63298B1/sr unknown
-
2018
- 2018-06-14 IL IL260043A patent/IL260043A/en unknown
- 2018-07-09 CL CL2018001868A patent/CL2018001868A1/es unknown
- 2018-07-10 SA SA518391996A patent/SA518391996B1/ar unknown
- 2018-07-12 PH PH12018501502A patent/PH12018501502A1/en unknown
- 2018-07-16 CO CONC2018/0007440A patent/CO2018007440A2/es unknown
-
2020
- 2020-09-17 US US17/024,264 patent/US20200407409A1/en not_active Abandoned
- 2020-11-17 JP JP2020190846A patent/JP2021035989A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220720T1 (hr) | Analozi egf(a) s masnim kiselinama kao supstituentima | |
| Ikai et al. | Structure of aureobasidin A | |
| Mazurier et al. | Human lactotransferrin: molecular, functional and evolutionary comparisons with human serum transferrin and hen ovotransferrin | |
| RU2017125050A (ru) | Производные fgf21 и их применения | |
| RU2013147468A (ru) | Сайт-специфически монопегилированные аналоги эксендина и способ их получения | |
| HRP20210809T1 (hr) | Biciklični peptidni ligandi specifični za mt1-mmp | |
| JP2013543497A5 (enExample) | ||
| US10647742B2 (en) | Method for synthesizing etelcalcetide | |
| HRP20221054T1 (hr) | Novi analozi glp-1 | |
| DK1086124T3 (da) | Nye cyclosporiner | |
| JP2010539915A5 (enExample) | ||
| DK2049562T3 (da) | Peptider med farmakologisk virkning til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer | |
| CA2899384A1 (en) | Antifouling materials | |
| CA2337923A1 (en) | Peptide antibiotics | |
| AU2022209272A1 (en) | Stable modulators of gamma-c-cytokine activity | |
| SE454699B (sv) | Peptider och lekemedel innehallande desamma | |
| JPH03504496A (ja) | 水素結合の共有結合置換により安定化されたポリペプチド | |
| US8541365B2 (en) | Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof | |
| MY147920A (en) | Antibacterial and antiviral peptides from actinomadura namibiensis | |
| BRPI0609783A8 (pt) | composto, utilização do mesmo, composição farmacêutica ou cosmética, e, utilização cosmética de um composto | |
| Dahiya | Synthetic and pharmacological studies on longicalycinin A | |
| SI3191504T1 (en) | Ezrine-derived peptides and their pharmaceutical compositions | |
| ATE555120T1 (de) | Neue antimikrobielle peptide und ihre anwendung | |
| Nair et al. | Formation of a pseudo-β-hairpin motif utilizing the Ant–Pro reverse turn: consequences of stereochemical reordering | |
| Janusz et al. | High potency dipeptide sweeteners. 1. L-aspartyl-D-phenylglycine esters |